Results 101 to 110 of about 1,382 (158)

Dabigatran Prevents Lipopolysaccharide-Mediated Apoptosis in Zebrafish Through a Thrombin-Independent Mechanism. [PDF]

Shock
Fleischmann AIT, Woodhams WH, Mouayed R, Joseph T, Sui X, Yaman M, Oehlers S, Shavit JA, Jacob VA.   +8 more
europepmc   +1 more source

Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the <i>Staphylococcus aureus</i> Network Adaptive Platform (SNAP) randomised controlled trial. [PDF]

BMJ Open
McDonald EG, Cheng MP, Davis JS, Goodman AL, Lawler PR, Marsh J, Mertz D, Paul M, Rodriguez-Baño J, Siegal DM, Tong SY, Walls G, Lee TC, SNAP Global Trial Steering Committee.   +13 more
europepmc   +1 more source

Not so fast, antithrombin!

Blood, 2023
Majumder R.
europepmc   +1 more source

Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran. [PDF]

Sci Rep
Kim JM, Bang YY, Kim KA, Park JW, Park JY.   +4 more
europepmc   +1 more source

Is bivalirudin ready for a comeback? Pros and cons. [PDF]

EuroIntervention
Stone GW, Akinmolayemi O, Stables RH.
europepmc   +1 more source

The Effect of Postoperative Antithrombin Supplementation on the Inflammatory and Coagulation Status of a Surgically Treated Patient With a Malignant Tumor in the Small Pelvis-Case Series. [PDF]

Cancer Rep (Hoboken)
Lazović R, Šarenac O.
europepmc   +1 more source

Clinical and Molecular Characterization of Nine Novel Antithrombin Mutations. [PDF]

Int J Mol Sci
Kállai J, Gindele R, Pénzes-Daku K, Balogh G, Bogáti R, Bécsi B, Katona É, Oláh Z, Ilonczai P, Boda Z, Róna-Tas Á, Nemes L, Marton I, Bereczky Z.   +13 more
europepmc   +1 more source

Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants. [PDF]

Br J Clin Pharmacol
Yang DZ, Zhou L, Winton JA, Matschke KT, Kantaridis C, Doyle K, Lee KC, Chen N, Zhang Y, Tan W.   +9 more
europepmc   +1 more source

New perspectives for anticoagulation in non-rheumatic atrial fibrillation: oral antithrombins [PDF]

, 2004
SCARDI S, GIANSANTE, CARLO
core  

Dabigatran-based versus warfarin-based triple antithrombotic regimen with a 1-month intensification after coronary stenting in patients with nonvalvular atrial fibrillation (COACH-AF PCI). [PDF]

BMC Med
Liang M, Jin J, Zhao R, Li H, Chen S, Liu L, Xu P, Wang W, Cheng X, Chen X, Tao L, Zhang Q, Yang M, Zeng C, Li L, Zheng Y, Chen H, Guo J, Zhong Z, Bi Y, Cheng B, Zhou Y, Wang H, Zhang Y, Qiu M, Zhang Q, Zhang P, Zhang J, Wang Z, Li Y, Han Y.   +30 more
europepmc   +1 more source